FDA Accepts IDE Supplement for INTERCEPT Blood System Treatment of Ebola Convalescent Plasma Business Wire via Yahoo! Finance Nov 21 05:30am Cerus Corporation today announced that the U.S. Food and Drug Administration has accepted Cerus’ clinical protocol to make the INTERCEPT Blood System for plasma available under an Investigational Device Exemption for treatment of convalescent plasma collected from Ebola disease survivors for passive immune therapy.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.